Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Vergiss die Indizes - Forge steigt um 40 %, während der S&P & Dow fällt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W7D4 | ISIN: CA05156V1022 | Ticker-Symbol: IKAP
Tradegate
24.04.25
16:00 Uhr
7,060 Euro
-0,042
-0,59 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
AURINIA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
AURINIA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,1667,23219:07
7,1667,23019:07

Aktuelle News zur AURINIA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.03.Aurinia Pharmaceuticals stock climbs on insider buying6
27.02.Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations6
27.02.Aurinia Pharma reports mixed Q4 results; initiates FY25 outlook15
27.02.Aurinia Pharmaceuticals Inc. - 10-K, Annual Report3
27.02.Aurinia Pharmaceuticals Inc. - 8-K, Current Report1
AURINIA PHARMACEUTICALS Aktie jetzt für 0€ handeln
08.11.24Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets15
07.11.24Aurinia stock jumps 14% on Q3 earnings, restructuring announcement13
07.11.24More turbulence at Aurinia as autoimmune drugmaker lays off 45% of workforce3
07.11.24Aurinia Pharma GAAP EPS of $0.10 beats by $0.09, revenue of $67.77M beats by $10.08M6
07.11.24Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development211ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months...
► Artikel lesen
07.11.24Aurinia Pharmaceuticals Inc. - 10-Q, Quarterly Report-
07.11.24Aurinia Pharmaceuticals Inc. - 8-K, Current Report-
06.11.24Aurinia Pharma Q3 2024 Earnings Preview2
13.08.24On behalf of Lucien Selce: Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board425Highlights Damning Annual General Meeting Results, Which Show That Four of the Company's Nine Directors Failed to Receive a Majority of the Votes Calls on the Company to Appoint Two Shareholder...
► Artikel lesen
01.08.24Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results213ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the second quarter and six months...
► Artikel lesen
07.06.24ILJIN SNT Co., Ltd. Announces Its Intention to Vote Against Aurinia Pharmaceuticals's Revised Equity Incentive Plan Proposal598SEOUL, South Korea, June 7, 2024 /PRNewswire/ -- Dear Fellow Shareholders, ILJIN SNT Co., Ltd. ("ILJIN") is a long-standing investor of Aurinia Pharmaceuticals Inc. ("Aurinia" or...
► Artikel lesen
05.06.24Aurinia Pharmaceuticals Inc.: Aurinia Presents Safety and Efficacy Profile of LUPKYNIS for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024359Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in Vienna...
► Artikel lesen
03.06.24On behalf of Lucien Selce: Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf437Removing CEO and Director Peter Greenleaf from the Company Would Pave the Way for a Superior Board and Strategy That Would Rejuvenate Aurinia Lucien Selce, who owns approximately 2.2% of the outstanding...
► Artikel lesen
21.05.24ILJIN SNT Co., Ltd. Calls for Board Restructure at Aurinia Pharmaceuticals458SEOUL, South Korea, May 20, 2024 /PRNewswire/ -- Fellow Aurinia Shareholders, ILJIN SNT Co., Ltd. and its affiliates (collectively, "ILJIN") is a long-term holder of more than 5%...
► Artikel lesen
07.05.24On behalf of Lucien Selce: Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value423Outlines Concerns Regarding the Company's Current Strategy and Board Composition and Offers Superior Paths to Improving Performance and Market Penetration Lucien Selce, who owns approximately 2.2%...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1